股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | | | 致：香港交易及結算所有限公司 公司名稱: 瑞爾集團有限公司 呈交日期: 2025年12月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06639 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 1,250,000,000 | USD | | 0.02 USD | | 25,000,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 1,250,000,000 | USD | | 0.02 USD | | 25,000,000 | 本月底法定/註冊股本總額： USD 25,000,000 FF301 第 1 頁 共 1 ...

Core Viewpoint - 瑞尔集团 has announced a delay in the publication of its interim results, leading to a suspension of its shares trading until the results are released [1] Group 1 - 瑞尔集团's shares will be suspended from trading starting December 1, 2025, at 9:00 AM [1] - The suspension will remain in effect until the publication of the 2025 interim results [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 R Arrail Group Limited 本公告乃由瑞爾集團有限公司（「本公司」，連同其子公司及可變利益實體，統 稱「本集團」）董事（「董事」）會（「董事會」）根據香港聯合交易所有限公司（「聯交 所」）證券上市規則（「上市規則」）第13.09條及香港法例第571章證券及期貨條例第 XIVA部項下的內幕消息條文（定義見上市規則）作出。 延遲刊發中期業績 董事會及其轄下審計委員會（「審計委員會」）接獲本公司審計師（「審計師」）羅兵 咸永道會計師事務所發出的一封日期為2025年11月24日的信函（「該信函」），當中 審計師載明其審閱（「2025年中期審閱」）本集團截至2025年9月30日止六個月的中 期簡明合併財務資料（「2025年中期業績」）過程中所遇到的一個需要進一步調查的 事項（「該事項」）。 茲提述本公司與Beier Holdings Limited（一家於英屬維爾京群島註冊成立的公 司，由鄒其芳 ...

Core Viewpoint - 瑞尔集团's stock rose over 7% in early trading, reflecting positive market sentiment ahead of its upcoming board meeting to approve mid-term results [1] Financial Performance - 瑞尔集团预计在11月28日的董事会会议上审批中期业绩 [1] - The company has issued a profit warning, forecasting a pre-tax profit of no less than 20 million HKD, a significant increase from 7.4 million HKD in the same period last year [1] - The profit increase is attributed to operational improvements driven by AI-enabled clinical and business management systems, a rebound in patient demand and service volume, and strict cost reduction and efficiency enhancement measures [1]

Core Viewpoint - 瑞尔集团 (06639.HK) experienced a significant increase in stock price, rising over 7% in early trading, indicating positive market sentiment towards the company [1] Group 1 - The stock price of 瑞尔集团 rose by 7.43%, reaching 1.88 HKD per share [1] - The trading volume amounted to 11.2282 million HKD, reflecting active investor interest [1]

Core Viewpoint - 瑞尔集团's stock rose over 7% in early trading, reflecting positive market sentiment ahead of its upcoming board meeting to approve mid-term results [1] Financial Performance - 瑞尔集团预计在11月28日的董事会会议上审批中期业绩 [1] - The company has issued a profit warning, projecting a pre-tax profit of no less than 20 million HKD, a significant increase from 7.4 million HKD in the same period last year [1] - The profit increase is attributed to operational improvements from AI-enabled clinical and business management systems, a rebound in patient demand and service volume, and strict cost reduction and efficiency enhancement measures [1]

Core Viewpoint - 瑞尔集团's stock rose over 7% in early trading, reflecting positive market sentiment ahead of its upcoming board meeting to approve mid-term results [1] Financial Performance - The company anticipates a pre-tax profit of no less than 20 million HKD for the reporting period, a significant increase from 7.4 million HKD in the same period last year [1] - The profit increase is attributed to operational improvements driven by AI-enabled clinical and business management systems, a rebound in patient demand and service volume, and strict cost reduction and efficiency enhancement measures [1]

Core Viewpoint - 瑞尔集团预计在2026财年半年报中实现除所得税前利润不少于2000万元，较上年同期的740万元显著提升，主要得益于AI赋能的运营提升、患者需求回升及严格的降本增效计划 [1] Financial Performance - 瑞尔集团在2025财年半年报中实现收入约16.88亿元，同比仅减少3.3%，净利润增至1620万元，同比增长20.5% [11] - 公司在2024财年中，累计回购1736.35万股，占总股本比例达到3.08% [5] - 2024年，瑞尔集团的股价经历波动，尽管回购未能有效支撑股价，但在回购策略调整后，股价有所回升 [7][10] Market Conditions - 2024年国内医疗健康产业融资交易数量下降37.6%，融资总额减少33%，显示出行业整体遇冷 [9] - 口腔行业在2024年仅发生13起融资，占总融资交易数的1.6%，融资总额约9亿元，占总融资额的12.32% [9] - 行业内中小口腔诊所面临批量倒闭，2024年注销量同比增长约45% [9] Strategic Shift - 瑞尔集团的发展策略从扩张转向稳健，专注于现有诊所的精细化管理，取得一定成效 [10] - 公司在2025财年半年报中显示，扩店放缓在一定程度上缓解了对盈利的负面影响，表现在实现正增长 [10][11] Stock Performance - 瑞尔集团股价在2023年7月达到阶段性高点2.90港元后，经历了近4个月的下行周期，最低跌至1.59港元，跌幅达45.17% [1] - 随着港股通资金抛压影响减弱，瑞尔集团的持股比例在9月后几乎未再减少，显示出市场信心的恢复 [2][4]

Core Viewpoint - 瑞尔集团 expects to achieve a pre-tax profit of no less than 20 million yuan for the first half of the 2026 fiscal year, a significant increase from 7.4 million yuan in the same period last year, primarily due to AI-enabled operational improvements, rising patient demand, and strict cost control measures [1] Financial Performance - The company reported a pre-tax profit expectation of at least 20 million yuan for the first half of the 2026 fiscal year, compared to 7.4 million yuan in the previous year [1] - Revenue for the first half of the 2025 fiscal year was approximately 1.688 billion yuan, a year-on-year decrease of 3.3%, while net profit increased to 16.2 million yuan, a year-on-year growth of 20.5% [14] Stock Performance - Following the earnings announcement, the stock price rose by 9.43%, ending a six-day decline, after reaching a low of 1.59 HKD, down 45.17% from a peak of 2.90 HKD [1] - The company has been in a downtrend for nearly four months, with a significant drop in stock price despite previous recovery efforts [1][8] Market Dynamics - The domestic healthcare investment market saw a 37.6% decrease in financing transactions in 2024, with the oral healthcare sector facing challenges, including a 45% increase in the number of clinic closures [10][11] - The average profit margin in the oral healthcare industry has plummeted from 28% in 2019 to 9% [10] Strategic Shift - The company has shifted its strategy from aggressive expansion to a focus on optimizing existing clinics, which has led to improved management and operational efficiency [12][14] - The number of clinics remained stable, with 123 locations across 15 cities, indicating a pause in expansion to mitigate negative impacts on profitability [13][14] Share Buyback Strategy - The company engaged in share buybacks to stabilize market confidence, repurchasing 17.36 million shares in 2024, representing 3.08% of total shares [5] - A "small step fast run" strategy was adopted for buybacks in 2024, with 21 transactions totaling approximately 1.543 million shares, or 0.27% of total shares [6][8] Valuation Metrics - The company's price-to-book (PB) ratio is currently at 0.51, significantly lower than the industry average of 1.63, indicating potential for stock price recovery [14]

Core Viewpoint - 瑞尔集团 (6639.HK) expects a significant increase in profit for the six months ending September 30, 2025, projecting a pre-tax profit of no less than RMB 20 million, compared to approximately RMB 7.4 million in the same period last year [1] Group 1: Financial Performance - The projected pre-tax profit increase is attributed to operational improvements driven by AI-enabled clinical and business management systems [1] - The rise in patient demand and service volume is also a contributing factor to the expected profit growth [1] - The company has implemented strict cost reduction and efficiency enhancement plans, further supporting the anticipated profit increase [1]